Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Aurinia Completes Final Patient Treatment in Dry Eye Study
by Zacks Equity Research
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
Satsuma Plunges on Disappointing Data on Migraine Treatment
by Zacks Equity Research
Satsuma (STSA) tanks as late-stage study of STS101 (dihydroergotamine [DHE] nasal) powder as an acute treatment for migraine disappoints.
3 Coronavirus-Led Threats to MedTech That May Linger
by Urmimala Biswas
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
Roche Acquires Stratos Genomics, Presents Data on NMOSD Drug
by Zacks Equity Research
Roche (RHHBY) acquires Stratos Genomics to advance the development of its nanopore sequencer as well as releases positive data on its NMOSD Drug.
Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y
by Zacks Equity Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
by Zacks Equity Research
Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.
Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.
AbbVie's (ABBV) Q1 Earnings and Sales Surpass Estimates
by Zacks Equity Research
AbbVie (ABBV) beats on earnings and revenues in the first quarter of 2020. Shares up in pre-market trading.
Allergan (AGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Allergan (AGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs
by Zacks Equity Research
Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
by Zacks Equity Research
Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
Top-Ranked ETFs & Stocks to Buy From Bargain Industries
by Sweta Killa
Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently undervalued and have a solid Zacks Rank.
Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Allergan (AGN) Down 5.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval
by Zacks Equity Research
Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
by Zacks Equity Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates
by Zacks Equity Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.
Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) reports a wider loss in the fourth quarter, while sales surpass expectations.
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
by Zacks Equity Research
Zacks Value Trader Highlights: AbbVie, Allergan, Occidental, Chevron and CVS
One of Your Stock Investments is Being Acquired: Now What?
by Tracey Ryniec
One of your companies gets a buyout offer and the shares soar. There might be different strategies for traders and investors on what to do next.
Ironwood (IRWD) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter as well. Stock up.